Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimavanserin - ACADIA Pharmaceuticals

Next Previous
X
Search
Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 29 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Amides; Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor antagonists; Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Major depressive disorder; Schizophrenia
  • Phase II/III Behavioural disorders
  • Phase II Agitation; Insomnia
  • No development reported Psychiatric disorders
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia

Most Recent Events

  • 15 Aug 2024 ACADIA Pharmaceuticals terminates a phase III trial for Schizophrenia (Adjunctive treatment, Treatment-experienced) in USA, Argentina, Bulgaria, Canada, Croatia, Czech Republic, Hungary, Italy, Lithuania, Poland, Russia, Serbia, Spain, and Ukraine (PO) (NCT03121586)
  • 11 Mar 2024 Efficacy and adverse events data from a phase III ADVANCE-2 trial in Schizophrenia released by Acadia Pharmaceuticals
  • 13 Dec 2023 US District Court for the District of Delaware granted summary judgment to Acadia Pharmaceuticals against MSN Laboratories, MSN Pharmaceuticals and other ANDA filers, confirming the validity of the NUPLAZID® '740 composition of matter patent in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top